Anti-pd1 antibodies and their use as therapeutics and diagnostics
AssigneeBeiGene Switzerland GmbH
InventorsKang LI, Tong ZHANG, Jing SONG, Lanlan XU, Qi LIU, Hao PENG
Life of this patent
Estimating the term…
Abstract
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
Claims24
1-20. (canceled)
A fusion protein, designated P3Z, comprising an extracellular domain, a transmembrane domain, and a cytoplasmic domain, wherein:
- (a) the extracellular domain and the transmembrane domain comprise an amino acid sequence of human PD-1, and
- (b) the cytoplasmic domain comprises an amino acid sequence of human CD3ζ.
A fusion protein comprising a single chain variable fragment (scFv) of an anti-human CD3 mAb OKT3 fused to the C-terminal domain (113-220) of mouse CD8α according to SEQ ID NO:
- 89.
Dependencies are inferred from the claim text.